No abstract available
Keywords:
MEK inhibitor; adjuvant treatment; adoptive cell therapy; biological therapy; checkpoint inhibitors; immunotherapy; ipilimumab; melanoma; target therapy BRAF inhibitor.
MeSH terms
-
Antibodies, Monoclonal / therapeutic use
-
Antibodies, Monoclonal, Humanized / therapeutic use
-
Antineoplastic Agents, Immunological / therapeutic use*
-
Azetidines / therapeutic use
-
Chemotherapy, Adjuvant
-
Drug Discovery
-
Drug Therapy, Combination
-
Humans
-
Imidazoles / therapeutic use
-
Indoles / therapeutic use
-
Ipilimumab / therapeutic use
-
MAP Kinase Kinase 1 / antagonists & inhibitors
-
MAP Kinase Kinase 2 / antagonists & inhibitors
-
Melanoma / drug therapy*
-
Melanoma / secondary
-
Molecular Targeted Therapy
-
Neoplasm Metastasis
-
Nivolumab
-
Oximes / therapeutic use
-
Piperidines / therapeutic use
-
Protein Kinase Inhibitors / therapeutic use*
-
Proto-Oncogene Proteins B-raf / antagonists & inhibitors
-
Pyridones / therapeutic use
-
Pyrimidinones / therapeutic use
-
Skin Neoplasms / drug therapy*
-
Skin Neoplasms / pathology
-
Sulfonamides / therapeutic use
-
Vemurafenib
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Antineoplastic Agents, Immunological
-
Azetidines
-
Imidazoles
-
Indoles
-
Ipilimumab
-
Oximes
-
Piperidines
-
Protein Kinase Inhibitors
-
Pyridones
-
Pyrimidinones
-
Sulfonamides
-
Vemurafenib
-
Nivolumab
-
trametinib
-
atezolizumab
-
pembrolizumab
-
Proto-Oncogene Proteins B-raf
-
MAP Kinase Kinase 1
-
MAP Kinase Kinase 2
-
cobimetinib
-
dabrafenib